Standard BioTools Inc (NASDAQ:LAB) shares, rose in value on Thursday, March 27, with the stock price down by -4.20% to the previous day’s close as strong demand from buyers drove the stock to $1.14.
Actively observing the price movement in the last trading, the stock closed the session at $1.19, falling within a range of $1.13 and $1.21. The value of beta (5-year monthly) was 1.616. Referring to stock’s 52-week performance, its high was $3.04, and the low was $0.99. On the whole, LAB has fluctuated by -2.56% over the past month.
With the market capitalization of Standard BioTools Inc currently standing at about $432.04 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-25.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 169.2M, with a low estimate of 39.3M and a high estimate of 40.8M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 40.1M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LAB’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of LAB currently trading nearly 0.20% and -15.49% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.83, while the 7-day volatility ratio is showing 7.06% which for the 30-day chart, stands at 8.28%. Furthermore, Standard BioTools Inc (LAB)’s beta value is 1.52, and its average true range (ATR) is 0.09.
A comparison of Standard BioTools Inc (LAB) with its peers suggests the former has fared considerably weaker in the market. LAB showed an intraday change of -4.20% in last session, and over the past year, it shrunk by -57.78%%.
Data on historical trading for Standard BioTools Inc (NASDAQ:LAB) indicates that the trading volumes over the past 10 days have averaged 1.28 and over the past 3 months, they’ve averaged 1.94 million. According to company’s latest data on outstanding shares, there are 377.53 million shares outstanding.
Nearly 3.18% of Standard BioTools Inc’s shares belong to company insiders and institutional investors own 73.82% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 15.73 million shares as on 2025-03-14, resulting in a short ratio of 6.69. According to the data, the short interest in Standard BioTools Inc (LAB) stood at 837.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 13.5 million. The stock has fallen by -34.86% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LAB stock heading into the next quarter.
